Healthy individuals | | | |
No of reactivity peaks | 4–6 | 11–13 | 9–11 |
Main reactivities (no of individuals) | 55 kDa (25/65) | 38 kDa (41/65) | 32 kDa (50/65) |
| 63 kDa (37/65) | 55 kDa (65/65) | 48 kDa (55/65 |
| | 90 kDa (25/65) | 65 kDa (65/65)) |
| | | 90 kDa (30/65) |
| | | |
IPAH | | | |
No of reactivity peaks | 4–6 | 8–10 | 10–12 |
Main reactivities (no of patients) | 55 kDa (14/35) | 38 kDa (25/35) | 32 kDa (20/35) |
| 63 kDa (18/35) | 50 kDa (24/35) | 48 kDa (32/35) |
| | 55 kDa (35/35) | 57 kDa (28/35) |
| | 63 kDa (13/35) | 65 kDa (35/35) |
| | 90 kDa (16/35) | 90 kDa (10/35 |
| | | |
SSc with PAH | | | |
No of reactivity peaks | 4–6 | 8–10 | 8–10 |
Main reactivities (no of patients) | 55 kDa (4/10) | 27 kDa (5/10) | 32 kDa (8/10) |
| 63 kDa (5/10) | 38 kDa (9/10) | 48 kDa (8/10) |
| | 55 kDa (10/10) | 57 kDa (5/10) |
| | | 65 kDa (9/10) |
| | | |
Limited cutaneous SSc without PAH | | | |
No of reactivity peaks | 4–6 | 9–11 | 8–12 |
Main reactivities (no of patients) | 55 kDa (7/10) | 38 kDa (10/10) | 32 kDa (8/10) |
| 63 kDa (8/10) | 55 kDa (10/10) | 48 kDa (10/10) |
| | 90 kDa (10/10) | 65 kDa (9/10) |
| | | |
Diffuse SSc without PAH | | | |
No of reactivity peaks | 4–6 | 9–11 | 10–12 |
Main reactivities (no of patients) | 55 kDa (8/10) | 38 kDa (5/10) | 32 kDa (5/10) |
| 63 kDa (6/10) | 55 kDa (10/10) | 48 kDa (9/10) |
| | 80 kDa (5/10) | 65 kDa (1010) |
| | 90 kDa (5/10) | |